Exscientia (NASDAQ:EXAI) Shares Down 6.5%

Exscientia plc (NASDAQ:EXAI) shares traded down 6.5% during mid-day trading on Friday . The company traded as low as $4.76 and last traded at $4.76. 401,921 shares traded hands during trading, a decline of 42% from the average session volume of 687,854 shares. The stock had previously closed at $5.09.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley reaffirmed an “equal weight” rating and issued a $7.00 target price on shares of Exscientia in a report on Monday, April 22nd.

Exscientia Stock Performance

The company has a debt-to-equity ratio of 0.05, a current ratio of 6.22 and a quick ratio of 6.22. The firm’s 50 day simple moving average is $5.41 and its 200-day simple moving average is $5.81.

Exscientia (NASDAQ:EXAI) last posted its quarterly earnings results on Thursday, March 21st. The company reported ($0.42) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $0.02. Exscientia had a negative net margin of 737.10% and a negative return on equity of 36.44%. The firm had revenue of $3.10 million during the quarter, compared to analysts’ expectations of $41.63 million. As a group, equities research analysts expect that Exscientia plc will post -1.76 EPS for the current year.

Institutional Trading of Exscientia

A number of institutional investors have recently added to or reduced their stakes in the stock. Platinum Investment Management Ltd. increased its stake in Exscientia by 10.2% in the 3rd quarter. Platinum Investment Management Ltd. now owns 4,395,058 shares of the company’s stock valued at $19,866,000 after purchasing an additional 405,426 shares in the last quarter. Banque Pictet & Cie SA acquired a new position in shares of Exscientia during the 3rd quarter worth $1,040,000. Federated Hermes Inc. purchased a new stake in shares of Exscientia in the 3rd quarter worth about $362,000. DekaBank Deutsche Girozentrale acquired a new stake in Exscientia in the 3rd quarter valued at about $344,000. Finally, Jump Financial LLC purchased a new position in Exscientia during the 3rd quarter valued at about $165,000. Hedge funds and other institutional investors own 41.58% of the company’s stock.

About Exscientia

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy.